| Name | Title | Contact Details |
|---|
Avaxia is a leader in the growing field of gut-targeted therapeutics — orally administered, minimally absorbed drugs that are designed to act locally in the gastrointestinal tract. Avaxia’s lead clinical candidate, AVX-470, is an oral anti-TNF antibody for inflammatory bowel disease. This transformative product offers potentially improved safety and efficacy over existing anti-TNF therapies by focusing immune suppression only where needed in the diseased gut. Avaxia plans to use its gut-targeted antibody platform to develop therapeutics to address many other serious diseases such as type 2 diabetes, celiac disease, GI acute radiation syndrome and oral mucositis.
Affinergy, Inc. is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Durham, NC. To find more information about Affinergy, Inc., please visit www.affinergy.com
Henry J Austin Health Center is a Trenton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
HMI Corporation is a Brentwood, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
A leading specialty formulator and contract manufacturer of enzyme and probiotic-based dietary supplements.